Advertisement
ABBV or MRK or ZTS
Which Stock Would AI Choose? AbbVie (ABBV) vs. Merck (MRK) vs. Zoetis (ZTS) Stock Comparison
Key Takeaways
- ABBV has faced recent pressure, declining around 10% over the past month amid oncology softness, but YTD returns stand at about 8.6% with strong immunology growth from Skyrizi and Rinvoq.
- MRK shows robust YTD gains of over 14%, driven by Keytruda and recent acquisitions like Terns Pharmaceuticals, though facing a Keytruda patent cliff risk.
- ZTS lags with a 28% one-year drop and YTD declines near 7.5%, hit by safety concerns on Librela and fewer vet visits, despite Q4 revenue beats.
- Relative performance favors MRK in momentum, while ABBV offers stability; all three benefit from healthcare demand but vary in sector exposure.
- Analyst targets suggest upside: ABBV ~$249, MRK ~$128, ZTS ~$151, indicating recovery potential across the board.
Introduction
AbbVie (ABBV), Merck (MRK), and Zoetis (ZTS) represent key players in pharmaceuticals and animal health, sectors resilient amid market volatility. This stock comparison analyzes their recent performance, business drivers, and relative positioning in the current environment. Investors seeking defensive growth in healthcare or traders eyeing momentum shifts will find value in understanding contrasts between human therapeutics giants and the pure-play animal health leader. With ongoing pipeline advancements and sector tailwinds, these stocks offer insights into broader market sentiment and healthcare trends.
ABBV Overview and Recent Performance
AbbVie (ABBV), a research-based biopharmaceutical firm headquartered in North Chicago, focuses on immunology, oncology, neuroscience, and aesthetics. Key products like Skyrizi and Rinvoq have driven growth, offsetting Humira's post-patent erosion, with combined 2025 sales exceeding $26 billion and 2026 projections over $31 billion. Recent market activity saw shares slip below the 50-day SMA amid oncology sales weakness and aesthetics softness, contributing to a roughly 10% monthly decline. YTD returns hover at 8.6%, outperforming the S&P 500's 3.7%, supported by Q4 earnings beats and analyst targets near $249. Sentiment reflects caution on near-term headwinds but optimism for pipeline catalysts like Rinvoq expansions.
MRK Overview and Recent Performance
Merck (MRK), based in Rahway, New Jersey, operates in human health pharmaceuticals, vaccines, and animal health, with Keytruda as its blockbuster oncology drug. Recent developments include a $6.7 billion acquisition of Terns Pharmaceuticals to bolster its oncology pipeline and a $20 million collaboration with Quotient Therapeutics for inflammatory bowel disease. Shares have gained over 14% YTD, outpacing benchmarks, though recent weeks showed volatility with dips below key averages. Performance reflects Keytruda strength and diversification, with analyst targets around $128. Market sentiment balances growth from partnerships against patent cliff risks for flagship products.
ZTS Overview and Recent Performance
Zoetis (ZTS), the world's largest pure-play animal health company spun from Pfizer, develops medicines, vaccines, and diagnostics for pets and livestock. Recent quarters showed revenue growth, with Q4 2025 at $2.4 billion up 3%, but shares declined 28% over the past year due to Librela safety concerns, reduced veterinary visits, and guidance cuts. YTD returns near -7.5% trail peers, with recent trading volatile around $116. Analysts maintain a Buy rating with targets up to $151, citing livestock strength offsetting companion animal softness. Sentiment weighs recovery potential against demand headwinds.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI-powered trading bots, curated from hundreds available that trade thousands of tickers across stocks, ETFs, and crypto. Only the most suitable for current market conditions earn a spot among the 25 featured, with stats like annualized returns from +15% to +138%, win rates of 56-89%, and profit factors up to 4.72. These bots employ diverse strategies—trend following, swing trading, hedging volatility—across sectors like semiconductors, energy, and consumer staples, with trade durations from minutes to weeks and risk metrics like profit-to-drawdown ratios exceeding 22. Explore these for real-time signals and copy trading opportunities tailored to today's environment.
Head-to-Head Comparison
ABBV, MRK, and ZTS operate in healthcare but differ sharply: ABBV and MRK emphasize human pharma with immunology/oncology focus, while ZTS targets animal health. Growth drivers include ABBV's Skyrizi/Rinvoq momentum versus MRK's Keytruda dominance and acquisitions; ZTS relies on livestock resilience amid pet segment slowdowns. Recent momentum favors MRK (YTD +14%) over ABBV (-10% monthly) and ZTS (-28% yearly). Risk factors: patent cliffs for MRK/ABBV, regulatory/safety issues for ZTS. Sector exposure gives ZTS defensive livestock play; valuations show MRK cheapest on P/E, with sentiment tilting to MRK's catalysts despite broader pharma pressures.
Tickeron AI Verdict
Tickeron’s AI currently favors MRK based on superior trend consistency, YTD momentum, and pipeline catalysts like oncology deals, positioning it strongly relative to ABBV's recent dips and ZTS's prolonged weakness. While probabilities favor MRK for near-term outperformance amid healthcare stability, all three hold upside from sector tailwinds.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 2 FA rating(s) are green whileMRK’s FA Score has 4 green FA rating(s), and ZTS’s FA Score reflects 2 green FA rating(s).
- ABBV’s FA Score: 2 green, 3 red.
- MRK’s FA Score: 4 green, 1 red.
- ZTS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 6 TA indicator(s) are bullish while MRK’s TA Score has 4 bullish TA indicator(s), and ZTS’s TA Score reflects 5 bullish TA indicator(s).
- ABBV’s TA Score: 6 bullish, 4 bearish.
- MRK’s TA Score: 4 bullish, 4 bearish.
- ZTS’s TA Score: 5 bullish, 4 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +1.04% price change this week, while MRK (@Pharmaceuticals: Major) price change was -1.94% , and ZTS (@Pharmaceuticals: Generic) price fluctuated +3.84% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.21%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was +7.89%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.70%. For the same industry, the average monthly price growth was +8.17%, and the average quarterly price growth was +2.15%.
Reported Earning Dates
ABBV is expected to report earnings on Apr 29, 2026.
MRK is expected to report earnings on Apr 30, 2026.
ZTS is expected to report earnings on May 07, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.21% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Pharmaceuticals: Generic (+3.70% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| ABBV | MRK | ZTS | |
| Capitalization | 369B | 294B | 51.5B |
| EBITDA | 17.6B | 28.3B | 4.07B |
| Gain YTD | -7.305 | 13.958 | -2.319 |
| P/E Ratio | 87.92 | 16.36 | 20.33 |
| Revenue | 61.2B | 65B | 9.47B |
| Total Cash | N/A | N/A | 2.31B |
| Total Debt | 67.5B | 49.3B | 9.24B |
ABBV | MRK | ZTS | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 60 | 55 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 35 Fair valued | 21 Undervalued | 30 Undervalued | |
PROFIT vs RISK RATING 1..100 | 14 | 48 | 100 | |
SMR RATING 1..100 | 1 | 25 | 16 | |
PRICE GROWTH RATING 1..100 | 55 | 16 | 60 | |
P/E GROWTH RATING 1..100 | 40 | 28 | 85 | |
SEASONALITY SCORE 1..100 | n/a | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MRK's Valuation (21) in the Pharmaceuticals Major industry is in the same range as ZTS (30) in the Pharmaceuticals Generic industry, and is in the same range as ABBV (35) in the Pharmaceuticals Major industry. This means that MRK's stock grew similarly to ZTS’s and similarly to ABBV’s over the last 12 months.
ABBV's Profit vs Risk Rating (14) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (48) in the Pharmaceuticals Major industry, and is significantly better than the same rating for ZTS (100) in the Pharmaceuticals Generic industry. This means that ABBV's stock grew somewhat faster than MRK’s and significantly faster than ZTS’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as ZTS (16) in the Pharmaceuticals Generic industry, and is in the same range as MRK (25) in the Pharmaceuticals Major industry. This means that ABBV's stock grew similarly to ZTS’s and similarly to MRK’s over the last 12 months.
MRK's Price Growth Rating (16) in the Pharmaceuticals Major industry is somewhat better than the same rating for ABBV (55) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for ZTS (60) in the Pharmaceuticals Generic industry. This means that MRK's stock grew somewhat faster than ABBV’s and somewhat faster than ZTS’s over the last 12 months.
MRK's P/E Growth Rating (28) in the Pharmaceuticals Major industry is in the same range as ABBV (40) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for ZTS (85) in the Pharmaceuticals Generic industry. This means that MRK's stock grew similarly to ABBV’s and somewhat faster than ZTS’s over the last 12 months.
| ABBV | MRK | ZTS | |
|---|---|---|---|
| RSI ODDS (%) | 3 days ago 63% | N/A | 4 days ago 52% |
| Stochastic ODDS (%) | 3 days ago 58% | 3 days ago 62% | 3 days ago 62% |
| Momentum ODDS (%) | 3 days ago 65% | 3 days ago 47% | 3 days ago 61% |
| MACD ODDS (%) | 3 days ago 67% | 3 days ago 59% | 3 days ago 65% |
| TrendWeek ODDS (%) | 3 days ago 58% | 3 days ago 48% | 3 days ago 56% |
| TrendMonth ODDS (%) | 3 days ago 51% | 3 days ago 52% | 3 days ago 54% |
| Advances ODDS (%) | 11 days ago 57% | 18 days ago 52% | 6 days ago 52% |
| Declines ODDS (%) | 7 days ago 48% | 4 days ago 50% | 4 days ago 58% |
| BollingerBands ODDS (%) | 3 days ago 62% | 3 days ago 69% | 3 days ago 62% |
| Aroon ODDS (%) | 3 days ago 43% | 3 days ago 54% | 3 days ago 61% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BETE | 38.53 | 1.08 | +2.89% |
| ProShares Bitcoin & Eth Eq Wgh ETF | |||
| DFSV | 37.05 | 0.58 | +1.59% |
| Dimensional US Small Cap Value ETF | |||
| ENHU | 26.36 | 0.32 | +1.22% |
| iShares Enhanced Large Cap Core Actv ETF | |||
| SFEB | 25.15 | 0.28 | +1.13% |
| FT Vest U.S. Small Cap Mod Buf ETF-Feb | |||
| EIM | 9.89 | 0.02 | +0.22% |
| Eaton Vance Municipal | |||
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with PFE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | -0.29% | ||
| PFE - ABBV | 57% Loosely correlated | +1.25% | ||
| BMY - ABBV | 55% Loosely correlated | +2.05% | ||
| BIIB - ABBV | 51% Loosely correlated | +0.76% | ||
| AMGN - ABBV | 51% Loosely correlated | +1.69% | ||
| NVS - ABBV | 49% Loosely correlated | +1.50% | ||
More | ||||
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with PFE. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To MRK | 1D Price Change % | ||
|---|---|---|---|---|
| MRK | 100% | +3.13% | ||
| PFE - MRK | 63% Loosely correlated | +1.25% | ||
| BMY - MRK | 62% Loosely correlated | +2.05% | ||
| BIIB - MRK | 55% Loosely correlated | +0.76% | ||
| GSK - MRK | 54% Loosely correlated | +2.14% | ||
| AMGN - MRK | 54% Loosely correlated | +1.69% | ||
More | ||||
ZTS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with ELAN. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then ELAN could also see price increases.
| Ticker / NAME | Correlation To ZTS | 1D Price Change % | ||
|---|---|---|---|---|
| ZTS | 100% | +2.81% | ||
| ELAN - ZTS | 46% Loosely correlated | +2.38% | ||
| PRGO - ZTS | 38% Loosely correlated | +3.33% | ||
| VTRS - ZTS | 37% Loosely correlated | +4.78% | ||
| HLN - ZTS | 37% Loosely correlated | +1.67% | ||
| PAHC - ZTS | 36% Loosely correlated | +5.92% | ||
More | ||||